决策：何时、针对谁使用哪种 PARP 抑制剂。
The DecisionWhich PARP Inhibitor to Use for Whom and When.
机构信息
National Cancer Institute, Bethesda, Maryland.
出版信息
Clin Cancer Res. 2017 Dec 1;23(23):7155-7157. doi: 10.1158/1078-0432.CCR-17-2186. Epub 2017 Oct 3.
Abstract
Rucaparib, a polyADPribose polymerase inhibitor (PARPi), was approved recently for use in women with high-grade serous ovarian cancer (HGSOC). It is now one of three approved PARPi for use in recurrent ovarian cancer, a family of agents that has changed the HGSOC treatment landscape and outcome. .
摘要
鲁卡帕利，一种聚 ADP 核糖聚合酶抑制剂（PARPi），最近被批准用于治疗高级别浆液性卵巢癌（HGSOC）。它现在是三种已批准用于复发性卵巢癌的 PARPi 之一，这一类药物改变了 HGSOC 的治疗格局和结果。
相似文献
1
The DecisionWhich PARP Inhibitor to Use for Whom and When.决策：何时、针对谁使用哪种 PARP 抑制剂。
Clin Cancer Res. 2017 Dec 1;23(23):7155-7157. doi: 10.1158/1078-0432.CCR-17-2186. Epub 2017 Oct 3.
2
Activation of Wnt signaling promotes olaparib resistant ovarian cancer.Wnt 信号激活促进奥拉帕利耐药卵巢癌。
Mol Carcinog. 2019 Oct;58(10):1770-1782. doi: 10.1002/mc.23064. Epub 2019 Jun 10.
3
Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.蛋白质组学分析揭示低剂量 PARP 抑制剂诱导 BRCA1 突变型高级别浆液性卵巢癌细胞差异蛋白表达。
J Am Soc Mass Spectrom. 2022 Feb 2;33(2):242-250. doi: 10.1021/jasms.1c00215. Epub 2021 Dec 27.
4
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.PARP 抑制剂在卵巢癌中的应用：开拓与变革之旅。
Clin Cancer Res. 2018 Sep 1;24(17):4062-4065. doi: 10.1158/1078-0432.CCR-18-1314. Epub 2018 Jun 5.
5
Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.KRAS 扩增的 BRCA 缺陷型高级别浆液性卵巢癌中，PLK1 和 PARP1 的序贯靶向逆转了对 PARP 抑制剂的耐药性，并增强了铂类化疗。
Int J Mol Sci. 2022 Sep 17;23(18):10892. doi: 10.3390/ijms231810892.
6
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.维持性 PARP 抑制剂治疗铂敏感复发性卵巢癌患者无进展生存期改善的分子和临床预测因素：一项荟萃分析。
Cancer. 2021 Jul 15;127(14):2432-2441. doi: 10.1002/cncr.33517. Epub 2021 Mar 19.
7
How safe is rucaparib in ovarian cancer?鲁卡帕利在卵巢癌中的安全性如何？
Expert Opin Drug Saf. 2018 Dec;17(12):1249-1255. doi: 10.1080/14740338.2018.1550067. Epub 2018 Dec 11.
8
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.使用 PARP 抑制剂治疗卵巢癌患者。
Curr Treat Options Oncol. 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7.
9
Appropriate Selection of PARP Inhibitors in Ovarian Cancer.卵巢癌中PARP抑制剂的合理选择
Curr Treat Options Oncol. 2022 Jun;23(6):887-903. doi: 10.1007/s11864-022-00938-4. Epub 2022 Apr 12.
10
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.聚（ADP-核糖）聚合酶（PARP）抑制剂治疗卵巢癌。
Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4.
引用本文的文献
1
PARP Inhibitors in the Neoadjuvant Setting; A Comprehensive Overview of the Rationale for their Use, Past and Ongoing Clinical Trials.新辅助治疗中的PARP抑制剂；其应用原理、既往及正在进行的临床试验的全面概述
Curr Oncol Rep. 2025 May;27(5):533-551. doi: 10.1007/s11912-025-01669-z. Epub 2025 Apr 7.
2
ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients.基于循环肿瘤DNA（ctDNA）的液体活检揭示了早期乳腺癌患者更广泛的突变谱，以及与治疗耐药性和转移易感性相关的特征。
J Liq Biopsy. 2024 Dec 27;7:100284. doi: 10.1016/j.jlb.2024.100284. eCollection 2025 Mar.
3
Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer.新型恶二唑嗪衍生物GP - 2250在卵巢癌中的作用机制及合理联合用药
Cancer Med. 2024 Aug;13(15):e70031. doi: 10.1002/cam4.70031.
4
PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction and .PARP 抑制剂通过合成致死相互作用有效降低 MAPK 抑制剂耐药性黑素瘤细胞的生长，并与 MAPK 抑制剂协同作用。
Cancer Res Commun. 2023 Sep 5;3(9):1743-1755. doi: 10.1158/2767-9764.CRC-23-0101. eCollection 2023 Sep.
5
Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.皮肤肿瘤的同源重组缺陷（HRD）。
Int J Mol Sci. 2023 Jun 28;24(13):10771. doi: 10.3390/ijms241310771.
6
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study.卵巢癌的同源重组缺陷内检测：一项多机构的意大利用户研究。
J Clin Pathol. 2024 Jun 19;77(7):478-485. doi: 10.1136/jcp-2023-208852.
7
Advances in PARP Inhibitors for Prostate Cancer.前列腺癌PARP抑制剂的进展
Cancers (Basel). 2023 Mar 20;15(6):1849. doi: 10.3390/cancers15061849.
8
Precision Medicine for /-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition.用于/-突变型胰腺癌的精准医学及改善对PARP抑制治疗反应的新策略。
Cancers (Basel). 2022 Feb 11;14(4):897. doi: 10.3390/cancers14040897.
9
Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors.砷化合物使同源重组功能正常的卵巢癌对PARP抑制剂敏感。
Cell Death Discov. 2021 Sep 22;7(1):259. doi: 10.1038/s41420-021-00638-2.
10
Synthetic Lethality in Ovarian Cancer.卵巢癌中的合成致死性。
Mol Cancer Ther. 2021 Nov;20(11):2117-2128. doi: 10.1158/1535-7163.MCT-21-0500. Epub 2021 Sep 13.
本文引用的文献
1
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.奥拉帕利片作为 BRCA1/2 突变的铂敏感复发性卵巢癌患者的维持治疗（SOLO2/ENGOT-Ov21）：一项双盲、随机、安慰剂对照、III 期临床试验。
Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25.
2
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious Mutation-Associated Advanced Ovarian Cancer.美国食品药品监督管理局批准概要：芦卡帕利治疗携带有害突变相关的晚期卵巢癌患者。
Clin Cancer Res. 2017 Dec 1;23(23):7165-7170. doi: 10.1158/1078-0432.CCR-17-1337. Epub 2017 Jul 27.
3
The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality.DNA修复中的“双头怪”：临床合成致死性
Trends Cancer. 2016 Nov;2(11):646-656. doi: 10.1016/j.trecan.2016.10.014. Epub 2016 Nov 23.
4
PARP inhibitors: Synthetic lethality in the clinic.聚（ADP-核糖）聚合酶抑制剂：临床中的合成致死性
Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344. Epub 2017 Mar 16.
5
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.鲁卡帕利治疗复发铂类敏感型高级别卵巢癌（ARIEL2 研究第 1 部分）：一项国际多中心、开放标签、2 期临床试验。
Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.
6
Targeting the DNA Damage Response in Cancer.靶向癌症的 DNA 损伤反应。
Mol Cell. 2015 Nov 19;60(4):547-60. doi: 10.1016/j.molcel.2015.10.040.
7
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.联合 Cediranib 和奥拉帕利对比奥拉帕利单药治疗铂类敏感复发性卵巢癌患者的随机 2 期研究。
Lancet Oncol. 2014 Oct;15(11):1207-14. doi: 10.1016/S1470-2045(14)70391-2. Epub 2014 Sep 10.
8
Ovarian cancer.卵巢癌。
Lancet. 2014 Oct 11;384(9951):1376-88. doi: 10.1016/S0140-6736(13)62146-7. Epub 2014 Apr 21.
9
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.BRCA1/2 突变携带者卵巢癌中 PARP 抑制剂耐药后的化疗疗效：一项多机构研究。
Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6.
10
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.临床 PARP 抑制剂对 PARP1 和 PARP2 的捕获。
Cancer Res. 2012 Nov 1;72(21):5588-99. doi: 10.1158/0008-5472.CAN-12-2753.
Zotero 插件